SCHEMBL3103979

SCHEMBL3103979

Cc1noc(-c2ccc(C(=O)N3CCC(C(=O)NC4CCc5ccccc54)(c4ccccc4)CC3)cc2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.40
DDR1 Q08345 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MGLL Q99685 1/20 0.38
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
EPHX1 P07099 1/20 0.38
EPHX2 P34913 1/20 0.38
RECQL P46063 1/20 0.38
PDE2A O00408 1/20 0.38
SCD5 Q86SK9 1/20 0.37
GPR119 Q8TDV5 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13092265 1.00 TSHR (0.40) TSHRDDR1ALDH1A1HTTNPSR1
SCHEMBL3103971 0.86 TSHR (0.43) TSHRALDH1A1MGLLJAK2JAK1
SCHEMBL3100093 0.83 TSHR (0.44) TSHRALDH1A1NPSR1MGLLSCD5
SCHEMBL378371 0.81 CA12 (0.47) TSHRALDH1A1MGLLSCD5GPR119
SCHEMBL379082 0.80 CA12 (0.47) TSHRALDH1A1MGLLSCD5GPR119
SCHEMBL13092253 0.79 TSHR (0.44) TSHRALDH1A1MGLLSCD5GPR119
SCHEMBL13092311 0.78 TSHR (0.43) TSHRMGLLSCD5GPR119CA12
SCHEMBL378915 0.78 TSHR (0.43) TSHRALDH1A1HTTMGLLSCD5
SCHEMBL378032 0.78 TSHR (0.41) TSHRALDH1A1MGLLJAK2JAK1
SCHEMBL13092256 0.78 TSHR (0.44) TSHRALDH1A1MGLLSCD5GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 TSHR 895/4885DDR1 1882/4885ALDH1A1 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.